Social Avoidance News Today

*Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 *$44.4 million in cash and cash... | May 16, 2023

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 13, 2023

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 12, 2023

Certain personality traits may be linked to bad breath.

10.08.2022 - Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with ...

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported financial results for the second quarter ended June 30, 2022, and provided an overview of its recent...

CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Allos Pharma Inc (Allos), a late-stage pharmaceutical company developing therapeutics for neurod...

Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace

The company reported that cash on hand increased 57% year-over-year from $59.2 million to $93.1 million The RECONNECT trial, planned for the third quarter, will enroll around 200 children and adolescents with Fragile X Syndrome Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equivalents of $93.1 million on hand at the end of the first quar...

Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome The RECONNECT trial of the transdermal get is designed to evaluate its efficacy and safety in children and adolescents with FXS The company believes that the results, if positive, from RECONNECT will be sufficient to support the submission of a New Drug Application for Zygel Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (...